Meir Rinde | Authors


Sipuleucel-T Shows Potential With New Trial Data, But Questions Regarding Clinical Relevance Remain

April 15, 2019

Since the approval of sipuleucel-T for the treatment of minimally symptomatic metastatic castration-resistant prostate cancer in 2010, barriers to administration and the approval of competing drugs has tampered wide adoption of its use.

Novel Agents May Challenge Standard Therapy in Advanced HER2+ Breast Cancer

March 15, 2019

The treatment paradigm for HER2-positive breast cancer may be reshaped over the next several years, as head-to-head studies comparing new agents to the current standard of care begin to yield results, said Sara A. Hurvitz, MD.

Taking on the Hospital/Community Practice Cost Differential

January 24, 2018

Just as CMS moves ahead with payment reforms designed to reduce the total cost of hospital care, results from a new study show that cancer treatment costs remain significantly lower at community oncology clinics compared with hospitals.